We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

80 hedge funds and large institutions have $242M invested in TScan Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

21% more funds holding

Funds holding: 66 → 80 (+14)

6.67% more ownership

Funds ownership: 78.64% → 85.31% (+6.7%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less capital invested

Capital invested by funds: $272M → $242M (-$29.9M)

Holders
80
Holders Change
+14
Holders Change %
+21.21%
% of All Funds
1.16%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
31
Increased
19
Reduced
14
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.8M
2
GPP
Great Point Partners
Connecticut
+$7.41M
3
SC
Stempoint Capital
New York
+$6.66M
4
LP
LMR Partners
United Kingdom
+$5.24M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.87M
2
LCM
Laurion Capital Management
New York
-$2.38M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.37M
4
Goldman Sachs
Goldman Sachs
New York
-$1.77M
5
Citigroup
Citigroup
New York
-$854K
Name Holding Trade Value Shares
Change 		Change in
Stake
AGM
26
Alpine Global Management
New York
$804K +$1.08M +137,490 New
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$749K +$949K +120,454 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$682K +$919K +116,658 New
Charles Schwab
29
Charles Schwab
California
$661K +$715K +90,837 +411%
Walleye Capital
30
Walleye Capital
New York
$630K +$435K +55,187 +105%
Jane Street
31
Jane Street
New York
$579K -$426K -54,097 -35%
Northern Trust
32
Northern Trust
Illinois
$570K +$162K +20,552 +27%
Stifel Financial
33
Stifel Financial
Missouri
$558K -$47.3K -6,000 -6%
TCA
34
Troluce Capital Advisors
Puerto Rico
$543K +$731K +92,832 New
NW
35
NewEdge Wealth
Pennsylvania
$535K – – –
Wellington Management Group
36
Wellington Management Group
Massachusetts
$532K +$716K +90,941 New
Renaissance Technologies
37
Renaissance Technologies
New York
$468K +$260K +33,000 +70%
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$459K -$513K -65,151 -45%
BBHC
39
Brown Brothers Harriman & Co
New York
$445K +$599K +76,024 New
N
40
Nuveen
North Carolina
$409K +$551K +69,962 New
LCM
41
Laurion Capital Management
New York
$353K -$2.38M -302,084 -83%
American Century Companies
42
American Century Companies
Missouri
$278K +$123K +15,596 +49%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$274K +$369K +46,867 New
Bank of America
44
Bank of America
North Carolina
$256K +$107K +13,603 +45%
BCM
45
Bridgeway Capital Management
Texas
$224K -$197K -25,000 -39%
DIM
46
DC Investments Management
Virginia
$208K – – –
Goldman Sachs
47
Goldman Sachs
New York
$206K -$1.77M -224,880 -86%
Millennium Management
48
Millennium Management
New York
$163K -$2.87M -364,226 -93%
CIC
49
Cornercap Investment Counsel
Georgia
$134K +$181K +22,940 New
PFCS
50
Pale Fire Capital SE
Czech Republic
$126K – – –
1
2
3 4

TCRX Hedge Fund Activity: Q2 2024 in Review

80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2024, worth a combined $242M — down 11% from $272M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new TCRX positions and 16 closed out — a net gain of 15 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $2.87M.

  • 80 institutional investors held TScan Therapeutics (TCRX) as of Q2 2024, up from 66 in Q1 2024.
  • Funds reported $242M of TScan Therapeutics stock for Q2 2024, down 11% quarter-over-quarter.
  • 31 funds opened new TScan Therapeutics positions in Q2 2024 and 16 closed out, a net change of +15 holders.
  • The largest TScan Therapeutics buyer in Q2 2024 was BlackRock, an estimated $21.8M added.
  • The largest TScan Therapeutics seller in Q2 2024 was Millennium Management, an estimated $2.87M sold.

Based on aggregated 13F filings for Q2 2024.